SCHEMBL5477178

SCHEMBL5477178

C[C@H]1CN(c2ncccc2[N+](=O)[O-])CCN1C(=O)/C=C/c1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.46
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 5/20 0.43
MAPT P10636 5/20 0.43
ALDH1A1 P00352 3/20 0.43
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
AVPR1A P37288 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 1/20 0.42
POLB P06746 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
RBP4 P02753 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482298 1.00 GRM5 (0.46) GRM5KMT2AL3MBTL1MAPK1LMNA
SCHEMBL5477183 1.00 GRM5 (0.46) GRM5KMT2AL3MBTL1MAPK1LMNA
SCHEMBL5482297 1.00 GRM5 (0.46) GRM5KMT2AL3MBTL1MAPK1LMNA
SCHEMBL5483943 0.85 MAPT (0.57) GRM5KMT2AL3MBTL1LMNAMAPT
SCHEMBL5483941 0.85 MAPT (0.57) GRM5KMT2AL3MBTL1LMNAMAPT
SCHEMBL5485812 0.83 GRM1 (0.55) L3MBTL1LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL5487116 0.83 GRM1 (0.55) L3MBTL1LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL5485818 0.83 GRM1 (0.55) L3MBTL1LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL5487124 0.83 GRM1 (0.55) L3MBTL1LMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL5486528 0.81 GRM5 (0.44) GRM5KMT2AL3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US claimed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049578-A1 Cinnamamide compounds as metabotropic glutamate receptor antagonists GRM5, GRM1, GRM3 GRM5 1/4885KMT2A 1203/4885L3MBTL1 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.